Hao Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hao Chen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Dongjie Yan
Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
2 shared publications - Feng Wang
Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
2 shared publications - Yi Han
Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China
2 shared publications - Chunming Liu
Graduate School, Chengde Medical University
1 shared publication - Daqiang Sun
Department of Thoracic Surgery, Tianjin Chest Hospital (Affiliated Hospital of Tianjin University), Tianjin, China
1 shared publication - Han Zhang
Chest Hospital, Tianjin University, Tianjin 300072, China
1 shared publication
Latest Publications
- Open Access
Recurrence Pattern and Prognostic Value of Major Pathological Response in Patients with Locally Advanced Oesophageal Squamous Cell Carcinoma Treated with Neoadjuvant Immunochemotherapy: A Multicentre Retrospective Study
Background/Objectives: Major pathological response (MPR) has been suggested as a potential surrogate marker for assessing the efficacy of neoadjuvant therapy. However, its prognostic value and association with postoperative recurrence patterns remain unclear in patients with locally advanced oesophageal squamous cell carcinoma (ESCC) treated with neoadjuvant immunochemotherapy. This multicentre study aimed to investigate the relationship between MPR status, survival outcomes, and recurrence characteristics in this population. Methods: A total of 305 patients with locally advanced ESCC who received neoadjuvant immunochemotherapy followed by surgical resection at four medical centres in China between December 2019 and April 2024 were retrospectively enrolled in this study. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards regression models. Propensity score matching (PSM) was performed to balance baseline characteristics between patients with and without MPR, and survival outcomes and postoperative recurrence patterns were subsequently compared. Results: Among the 305 patients, 115 (37.7%) achieved MPR. Multivariate analysis identified MPR and the number of neoadjuvant treatment cycles as independent prognostic factors for both OS and RFS (p < 0.05). After PSM, patients with MPR showed significantly improved OS and RFS compared with those without (p < 0.05). Postoperative recurrence occurred less frequently in the MPR group than in the non-MPR group (13.9% vs. 42.1%, respectively; p < 0.05), with reductions in both locoregional and distant recurrence. Conclusions: In patients with locally advanced ESCC receiving neoadjuvant immunochemotherapy and surgery, achieving MPR is associated with improved survival outcomes and a lower risk of postoperative recurrence. MPR may serve as a useful prognostic indicator for this population.
Open AccessRecurrence Pattern and Prognostic Value of Major Pathological Response in Patients with Locally Advanced Oesophageal Squamous Cell Carcinoma Treated with Neoadjuvant Immunochemotherapy: A Multicentre Retrospective Study
Background/Objectives: Major pathological response (MPR) has been suggested as a potential surrogate marker for assessing the efficacy of neoadjuvant therapy. However, its prognostic value and association with postoperative recurrence patterns remain unclear in patients with locally advanced oesophageal squamous cell carcinoma (ESCC) treated with neoadjuvant immunochemotherapy. This multicentre study aimed to investigate the relationship between MPR status, survival outcomes, and recurrence characteristics in this population. Methods: A total of 305 patients with locally advanced ESCC who received neoadjuvant immunochemotherapy followed by surgical resection at four medical centres in China between December 2019 and April 2024 were retrospectively enrolled in this study. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards regression models. Propensity score matching (PSM) was performed to balance baseline characteristics between patients with and without MPR, and survival outcomes and postoperative recurrence patterns were subsequently compared. Results: Among the 305 patients, 115 (37.7%) achieved MPR. Multivariate analysis identified MPR and the number of neoadjuvant treatment cycles as independent prognostic factors for both OS and RFS (p < 0.05). After PSM, patients with MPR showed significantly improved OS and RFS compared with those without (p < 0.05). Postoperative recurrence occurred less frequently in the MPR group than in the non-MPR group (13.9% vs. 42.1%, respectively; p < 0.05), with reductions in both locoregional and distant recurrence. Conclusions: In patients with locally advanced ESCC receiving neoadjuvant immunochemotherapy and surgery, achieving MPR is associated with improved survival outcomes and a lower risk of postoperative recurrence. MPR may serve as a useful prognostic indicator for this population.
- Open Access
- 29 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2021
Prognostic and Diagnostic Value of Node-RADS for Non-Small Cell Lung Cancer Following Neoadjuvant Therapy: A Multicenter Cohort Study
Background/Objectives: The aim of this study was to evaluate the performance of the Node-RADS scoring system for predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC) after neoadjuvant therapy and to assess its prognostic value for overall survival (OS) and event-free survival (EFS). Methods: A total of 247 patients with non-small cell lung cancer (NSCLC) from three centers who underwent surgery after neoadjuvant therapy were retrospectively enrolled. Post-treatment Node-RADS scores were reassessed by radiologists based on preoperative contrast-enhanced CT images. Logistic regression analysis was used to evaluate the predictive value of Node-RADS for postoperative pathological lymph node metastasis, while Cox regression analysis was performed to assess its associations with OS and EFS. Kaplan–Meier analysis was used to compare survival differences among different Node-RADS risk groups. Results: A total of 247 patients were included in this study, comprising 211 men and 36 women, with a mean age of 63.40 ± 7.58 years. Post-treatment Node-RADS score was significantly associated with both OS and EFS. In multivariable Cox regression analysis, Node-RADS remained independently associated with OS (HR = 1.79, 95% CI: 1.50–2.15, p < 0.001) and EFS (HR = 1.41, 95% CI: 1.23–1.62, p < 0.001). Using a Node-RADS score of 3 as the cutoff value, patients in the high-risk group had significantly worse OS and EFS than those in the low-risk group (both p < 0.01). For the prediction of lymph node metastasis, the inclusion of post-treatment Node-RADS markedly improved the discriminatory performance of the model, with an AUC of 0.769, a sensitivity of 46.2%, and a specificity of 87.6%. Conclusions: The Node-RADS score may provide useful imaging information for patient-level assessment of residual lymph node metastasis risk and survival stratification in patients with NSCLC after neoadjuvant therapy. These findings suggest that the scoring system may support patient-level post-treatment risk assessment.
- 29 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2021
Open AccessPrognostic and Diagnostic Value of Node-RADS for Non-Small Cell Lung Cancer Following Neoadjuvant Therapy: A Multicenter Cohort Study
Background/Objectives: The aim of this study was to evaluate the performance of the Node-RADS scoring system for predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC) after neoadjuvant therapy and to assess its prognostic value for overall survival (OS) and event-free survival (EFS). Methods: A total of 247 patients with non-small cell lung cancer (NSCLC) from three centers who underwent surgery after neoadjuvant therapy were retrospectively enrolled. Post-treatment Node-RADS scores were reassessed by radiologists based on preoperative contrast-enhanced CT images. Logistic regression analysis was used to evaluate the predictive value of Node-RADS for postoperative pathological lymph node metastasis, while Cox regression analysis was performed to assess its associations with OS and EFS. Kaplan–Meier analysis was used to compare survival differences among different Node-RADS risk groups. Results: A total of 247 patients were included in this study, comprising 211 men and 36 women, with a mean age of 63.40 ± 7.58 years. Post-treatment Node-RADS score was significantly associated with both OS and EFS. In multivariable Cox regression analysis, Node-RADS remained independently associated with OS (HR = 1.79, 95% CI: 1.50–2.15, p < 0.001) and EFS (HR = 1.41, 95% CI: 1.23–1.62, p < 0.001). Using a Node-RADS score of 3 as the cutoff value, patients in the high-risk group had significantly worse OS and EFS than those in the low-risk group (both p < 0.01). For the prediction of lymph node metastasis, the inclusion of post-treatment Node-RADS markedly improved the discriminatory performance of the model, with an AUC of 0.769, a sensitivity of 46.2%, and a specificity of 87.6%. Conclusions: The Node-RADS score may provide useful imaging information for patient-level assessment of residual lymph node metastasis risk and survival stratification in patients with NSCLC after neoadjuvant therapy. These findings suggest that the scoring system may support patient-level post-treatment risk assessment.
- Open Access
- 25 January 2026
- Published by Springer Nature in Research Square
Assessment of the necessity of interlobar lymph node dissection in pathological stage IB non-small cell lung cancer: a propensity score-matched study
Background Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) being the most common type. Systematic lymph node dissection (SLND) is a standard procedure for NSCLC, but the necessity of routine interlobar lymph node dissection (ILND) in early-stage disease, particularly in stage IB NSCLC, remains debated. While ILND can be technically performed, its benefit in improving overall survival (OS) or recurrence-free survival (RFS) is unclear. The need for routine ILND remains controversial, with limited studies addressing its role in early-stage disease. This study aimed to assess whether ILND contributes to better survival outcomes in stage IB NSCLC. Methods We retrospectively analyzed 597 IB-stage NSCLC patients who underwent radical surgery for lung cancer at Sun Yat-Sen University Cancer Center from 1999 to 2009. We used the Cox proportional hazards regression model to analyze prognostic factors. After propensity-score matching (PSM), 458 patients were selected. We applied the Kaplan-Meier method and log-rank test to compare OS and RFS. Results Among 597 patients included in the study, 262 did not have ILND, while 335 did. According to whether the interlobar lymph nodes were dissected, 597 patients were divided into two groups. Significant differences were found between the two groups in laterality, number of dissected lymph node stations, and number of dissected lymph nodes (P < 0.05). Univariate and multivariate Cox analyses by the Cox proportional hazards model showed that age, family history of malignant tumors, and number of dissected lymph nodes were prognostic factors for OS (P < 0.05). For RFS, age and number of dissected lymph nodes were significant (P < 0.05). ILND was not associated with OS or RFS. After PSM, survival analysis using the Kaplan-Meier method and log-rank test showed no statistical association between ILND and OS or RFS (P > 0.05). Conclusion In stage IB NSCLC patients, ILND is not significantly associated with OS or RFS. Routine ILND is not necessary for early-stage NSCLC.
- 25 January 2026
- Published by Springer Nature in Research Square
Open AccessAssessment of the necessity of interlobar lymph node dissection in pathological stage IB non-small cell lung cancer: a propensity score-matched study
Background Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) being the most common type. Systematic lymph node dissection (SLND) is a standard procedure for NSCLC, but the necessity of routine interlobar lymph node dissection (ILND) in early-stage disease, particularly in stage IB NSCLC, remains debated. While ILND can be technically performed, its benefit in improving overall survival (OS) or recurrence-free survival (RFS) is unclear. The need for routine ILND remains controversial, with limited studies addressing its role in early-stage disease. This study aimed to assess whether ILND contributes to better survival outcomes in stage IB NSCLC. Methods We retrospectively analyzed 597 IB-stage NSCLC patients who underwent radical surgery for lung cancer at Sun Yat-Sen University Cancer Center from 1999 to 2009. We used the Cox proportional hazards regression model to analyze prognostic factors. After propensity-score matching (PSM), 458 patients were selected. We applied the Kaplan-Meier method and log-rank test to compare OS and RFS. Results Among 597 patients included in the study, 262 did not have ILND, while 335 did. According to whether the interlobar lymph nodes were dissected, 597 patients were divided into two groups. Significant differences were found between the two groups in laterality, number of dissected lymph node stations, and number of dissected lymph nodes (P < 0.05). Univariate and multivariate Cox analyses by the Cox proportional hazards model showed that age, family history of malignant tumors, and number of dissected lymph nodes were prognostic factors for OS (P < 0.05). For RFS, age and number of dissected lymph nodes were significant (P < 0.05). ILND was not associated with OS or RFS. After PSM, survival analysis using the Kaplan-Meier method and log-rank test showed no statistical association between ILND and OS or RFS (P > 0.05). Conclusion In stage IB NSCLC patients, ILND is not significantly associated with OS or RFS. Routine ILND is not necessary for early-stage NSCLC.